@Fpltitan Outright funny. Virios Therapeutics doesn’t even exist under that name anymore. The only mention in Tonix's recent 10k is: "Dogwood Therapeutics, Inc. (formerly Virios Therapeutics, Inc.) continues the development..." Hard to believe anyone still buying that fake merger story.
@Fpltitan Fake news. Tonix isn’t merging with anyone. The company is focused on Tonmya’s U.S. launch and its own pipeline, already keeping resources tight. Taking on an early‑stage biotech would only add cost and distraction. No verified signs of European expansion either.
@InvestorLatin@AscendingBio Abeona has been clear that the average patient requires ~2 treatment cycles to cover different wound areas, not just the ~150 most severe cases.
@Arhdan9 True, though we need to net out ~6 weeks of operating burn. Effective cash should be closer to ~$200m at that date, assuming the burn rate picked up with launch spend.
@YYDSxjm Clearly false. Tonix doesn’t hold a PRV. FDA approval for Tonmya was standard review, not priority. A PRV is too valuable to hide. If Tonix had one, it would be disclosed, and they wouldn’t be diluting shareholders.
@Arhdan9@SethLederman@TonixPharma $TNXP The CEO has invested ~$900k in shares (insider records), but reverse splits cut early holdings to nearly zero. He’s also been granted ~250k options with strike prices near $10 (SEC Form 4, Feb 5, 2025).
@bioinvestor24@rn_flex@CorleoneDon77 It's almost clear that VK2735 is "a me too of Lilly's Tirzepatide with the lipid tail COOH -> PO4," as @houndcl stated in an old post. The real question is whether the trivial COOH → PO4 modification is enough to allow commercialization without infringing Lilly's patents.
@rn_flex@bioinvestor24@CorleoneDon77 I think the big pharmas are very likely concerned that VK2735 is too similar to Tirzepatide to have valid IP protection.
@houndcl@bioinvestor24 Grok: "In short, if VK2735 and tirzepatide have identical amino acid sequences, VK2735 almost certainly infringes on tirzepatide’s patents, especially U.S. Patent No. 9,474,780."
@blake_mello Peter Lynch could very well be wrong though. What if the current share price may have already factored in more EPS growth than what is going to happen. Btw, I’m long $CRMD.
@HOThomasWPhelps@Randall7575 Very interesting to know, thanks. I wonder if Tezepelumab has fewer problems than Verekitug by targeting TSLP itself instead of the TSLP receptor?
@A_May_MD@PCM_bio If Viking is not a threat due to Sema's patent life, I'd assume the patent life to be the bigger threat to NVO.
It might simply take more time for a superior alternative to gain market share and impact Sema's sales.
@BIOTECHBATMAN@RNAiAnalyst@john_evans3 Could you use RNAi to decrease the abnormal protein and mRNA to produce the normal? So, combination of RNAi and mRNA technologies can achieve what gene editing can achieve?